C3N-04382
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 47.86858316
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- E2F_TARGETS+0.560
- G2M_CHECKPOINT+0.480
- INTERFERON_GAMMA_RESPONSE+0.460
- MYC_TARGETS_V1+0.440
- ALLOGRAFT_REJECTION+0.370
- DNA_REPAIR+0.280
- SPERMATOGENESIS+0.270
- MITOTIC_SPINDLE+0.260
- MYC_TARGETS_V2+0.220
Top 10 suppressed
- ANGIOGENESIS-0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- NOTCH_SIGNALING-0.410
- CHOLESTEROL_HOMEOSTASIS-0.400
- COAGULATION-0.340
- MYOGENESIS-0.340
- ESTROGEN_RESPONSE_EARLY-0.330
- PANCREAS_BETA_CELLS-0.310
- ESTROGEN_RESPONSE_LATE-0.290
- HEDGEHOG_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR11296816 | — | — | 0.896 |
| 2 | TCGA-AR-A24H-01A-11R-A169-07 | — | B | 0.872 |
| 3 | MBCProject_0454_T1_RNA | — | B | 0.871 |
| 4 | s0112318 | — | — | 0.868 |
| 5 | 1b0a23c2-785d-4a14-b673-86c97ceff401 | — | — | 0.856 |
| 6 | MBCProject_1542_T2_RNA | — | D | 0.854 |
| 7 | 77f39159-497c-47a0-bc8a-fb05dcd1826b | — | — | 0.851 |
| 8 | TCGA-58-A46M-01A-11R-A24H-07 | — | cohortSQ2 | 0.850 |
| 9 | SRR8518297 | — | E | 0.850 |
| 10 | 58c2404d-b213-4a7f-a8fc-11081a88091b | — | — | 0.845 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.370 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.220 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |
| COMPLEMENT | 0.010 | Inavolisib | — uncovered |